• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

在压力下学习：COVID-19 带来的将贯穿本世纪的经验教训。

Learning in times of stress: Lessons from COVID-19 that will last throughout this century.

机构信息

Medical Oncology Department, Hospital Universitario Central de Asturias, Oviedo, Spain.

Medical Oncology Department, Oncobell Program, IDIBELL Institut Català d'Oncologia, Hospital Duran i Reynals, CIBERONC, Barcelona, Spain.

出版信息

Eur J Intern Med. 2022 Feb;96:1-4. doi: 10.1016/j.ejim.2021.11.002. Epub 2021 Nov 12.

DOI:10.1016/j.ejim.2021.11.002
PMID:34801401
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8585637/
Abstract

Systems tend toward inertia until an external pressure pushes them toward change; thus, a situation of crisis such as the COVID-19 pandemic represents an opportunity for technological innovation. The prevailing need for treatments and vaccines has impelled innovation in the world of randomized clinical trials (RCT), resorting to ideas that had been floating around for a while. Is this merely a circumstantial phenomenon or are new methods here to stay?

摘要

系统往往倾向于保持惯性，直到外部压力迫使它们发生变化；因此，像 COVID-19 大流行这样的危机情况为技术创新提供了机会。对治疗方法和疫苗的迫切需求推动了随机临床试验 (RCT) 领域的创新，采用了一些之前已经存在的想法。这仅仅是一种偶然现象，还是新方法已经出现并将继续存在？

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3703/8585637/4444bd16e2e7/gr1_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3703/8585637/4444bd16e2e7/gr1_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3703/8585637/4444bd16e2e7/gr1_lrg.jpg

相似文献

1
Learning in times of stress: Lessons from COVID-19 that will last throughout this century.在压力下学习：COVID-19 带来的将贯穿本世纪的经验教训。
Eur J Intern Med. 2022 Feb;96:1-4. doi: 10.1016/j.ejim.2021.11.002. Epub 2021 Nov 12.
2
The UPMC OPTIMISE-C19 (OPtimizing Treatment and Impact of Monoclonal antIbodieS through Evaluation for COVID-19) trial: a structured summary of a study protocol for an open-label, pragmatic, comparative effectiveness platform trial with response-adaptive randomization.UPMC OPTIMISE-C19（通过对COVID-19的评估优化单克隆抗体的治疗及影响）试验：一项开放标签、务实、具有反应适应性随机化的比较有效性平台试验的研究方案结构化总结。
Trials. 2021 May 25;22(1):363. doi: 10.1186/s13063-021-05316-3.
3
Testing the efficacy and safety of BIO101, for the prevention of respiratory deterioration, in patients with COVID-19 pneumonia (COVA study): a structured summary of a study protocol for a randomised controlled trial.评估 BIO101 预防 COVID-19 肺炎患者呼吸恶化的疗效和安全性（COVA 研究）：一项随机对照试验研究方案的结构化总结。
Trials. 2021 Jan 11;22(1):42. doi: 10.1186/s13063-020-04998-5.
4
The REMAP-CAP (Randomized Embedded Multifactorial Adaptive Platform for Community-acquired Pneumonia) Study. Rationale and Design.REMAP-CAP（社区获得性肺炎的随机嵌入式多因素适应性平台）研究。原理与设计。
Ann Am Thorac Soc. 2020 Jul;17(7):879-891. doi: 10.1513/AnnalsATS.202003-192SD.
5
Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.COVID-19 住院成人患者使用伊马替尼的安全性和疗效：一项随机对照试验研究方案的结构化总结。
Trials. 2020 Oct 28;21(1):897. doi: 10.1186/s13063-020-04819-9.
6
Clinical trials and the COVID-19 pandemic.临床试验与新冠疫情
Hell J Nucl Med. 2020 Jan-Apr;23(1):4-5. doi: 10.1967/s002449912014.
7
Implementation of the Randomized Embedded Multifactorial Adaptive Platform for COVID-19 (REMAP-COVID) trial in a US health system-lessons learned and recommendations.在美国医疗体系中实施 COVID-19 随机嵌入式多因素适应性平台试验（REMAP-COVID）：经验教训和建议。
Trials. 2021 Jan 28;22(1):100. doi: 10.1186/s13063-020-04997-6.
8
A prospective, randomized, single-blinded, crossover trial to investigate the effect of a wearable device in addition to a daily symptom diary for the Remote Early Detection of SARS-CoV-2 infections (COVID-RED): a structured summary of a study protocol for a randomized controlled trial.一项前瞻性、随机、单盲、交叉试验，旨在研究可穿戴设备对 SARS-CoV-2 感染（COVID-RED）的远程早期检测的影响：一项随机对照试验研究方案的结构化总结。
Trials. 2021 Oct 11;22(1):694. doi: 10.1186/s13063-021-05643-5.
9
PROTECT Trial: A cluster-randomized study with hydroxychloroquine versus observational support for prevention or early-phase treatment of Coronavirus disease (COVID-19): A structured summary of a study protocol for a randomized controlled trial.PROTECT 试验：羟氯喹对比观察支持用于预防或 COVID-19 早期治疗的一项集群随机对照研究：一项随机对照试验研究方案的结构化总结。
Trials. 2020 Jul 31;21(1):689. doi: 10.1186/s13063-020-04527-4.
10
A phase II, single-center, double-blind, randomized placebo-controlled trial to explore the efficacy and safety of intravenous melatonin in patients with COVID-19 admitted to the intensive care unit (MelCOVID study): a structured summary of a study protocol for a randomized controlled trial.一项评估 ICU 收治的 COVID-19 患者静脉用褪黑素的疗效和安全性的 II 期、单中心、双盲、随机安慰剂对照试验（MelCOVID 研究）：一项随机对照试验研究方案的结构摘要。
Trials. 2020 Aug 5;21(1):699. doi: 10.1186/s13063-020-04632-4.

引用本文的文献

1
Bayesian versus frequentist clinical research now and then: Lessons from the Greco-Roman medical scholarship.贝叶斯与频率学派的临床研究今昔：来自古希腊罗马医学学术的教训
Ethics Med Public Health. 2022 Aug;23:100805. doi: 10.1016/j.jemep.2022.100805. Epub 2022 Jun 10.

本文引用的文献

1
Therapeutic Anticoagulation with Heparin in Noncritically Ill Patients with Covid-19.COVID-19 非危重症患者的肝素治疗性抗凝。
N Engl J Med. 2021 Aug 26;385(9):790-802. doi: 10.1056/NEJMoa2105911. Epub 2021 Aug 4.
2
Prediction of quality of life in early breast cancer upon completion of adjuvant chemotherapy.辅助化疗完成后早期乳腺癌患者生活质量的预测
NPJ Breast Cancer. 2021 Jul 13;7(1):92. doi: 10.1038/s41523-021-00296-8.
3
Critical reappraisal of phase III trials with immune checkpoint inhibitors in non-proportional hazards settings.
在非比例风险环境下对免疫检查点抑制剂的 III 期临床试验进行批判性再评价。
Eur J Cancer. 2020 Sep;136:159-168. doi: 10.1016/j.ejca.2020.06.003. Epub 2020 Jul 19.
4
Rationale and Design of ORCHID: A Randomized Placebo-controlled Clinical Trial of Hydroxychloroquine for Adults Hospitalized with COVID-19.ORCHID 研究的原理和设计：羟氯喹治疗 COVID-19 成年住院患者的随机安慰剂对照临床试验。
Ann Am Thorac Soc. 2020 Sep;17(9):1144-1153. doi: 10.1513/AnnalsATS.202005-478SD.
5
Remdesivir for the Treatment of Covid-19 - Final Report.瑞德西韦治疗 COVID-19 的疗效 - 最终报告。
N Engl J Med. 2020 Nov 5;383(19):1813-1826. doi: 10.1056/NEJMoa2007764. Epub 2020 Oct 8.
6
A Trial of Lopinavir-Ritonavir in Covid-19.洛匹那韦-利托那韦治疗新冠病毒病的一项试验
N Engl J Med. 2020 May 21;382(21):e68. doi: 10.1056/NEJMc2008043. Epub 2020 May 5.
7
The REMAP-CAP (Randomized Embedded Multifactorial Adaptive Platform for Community-acquired Pneumonia) Study. Rationale and Design.REMAP-CAP（社区获得性肺炎的随机嵌入式多因素适应性平台）研究。原理与设计。
Ann Am Thorac Soc. 2020 Jul;17(7):879-891. doi: 10.1513/AnnalsATS.202003-192SD.
8
Optimizing the Trade-off Between Learning and Doing in a Pandemic.在大流行期间优化学习与实践之间的权衡。
JAMA. 2020 May 19;323(19):1895-1896. doi: 10.1001/jama.2020.4984.
9
A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19.洛匹那韦-利托那韦治疗成人重症 COVID-19 患者的临床试验。
N Engl J Med. 2020 May 7;382(19):1787-1799. doi: 10.1056/NEJMoa2001282. Epub 2020 Mar 18.
10
Effects of a Resuscitation Strategy Targeting Peripheral Perfusion Status versus Serum Lactate Levels among Patients with Septic Shock. A Bayesian Reanalysis of the ANDROMEDA-SHOCK Trial.以外周灌注状态为目标的复苏策略与脓毒性休克患者血清乳酸水平的影响。ANDROMEDA-SHOCK 试验的贝叶斯再分析。
Am J Respir Crit Care Med. 2020 Feb 15;201(4):423-429. doi: 10.1164/rccm.201905-0968OC.